Skip to Main Content

Kim E. Nichols, MD

Member, St. Jude Faculty

Director, Cancer Predisposition Division

On this page:

Contact Information

Kim E. Nichols, MD

Cancer Predisposition

MS 1170, Room I3311

St. Jude Children's Research Hospital

262 Danny Thomas Place

MemphisTN 38105-3678

Quick Facts

Nichols was elected as a Member of the Association of American Physicians in 2025 in recognition of her outstanding contributions to the medical field and a commitment to fostering innovation and collaboration among physician scientists.

Nichols will host the upcoming St. Jude Cancer Predisposition Symposium titled At the Crossroads: Intersection of Germline Predisposition & Pediatric Oncology Clinical Care & Research.

Education

BA – Dartmouth College MD – Duke University School of Medicine

Honors & Awards

  • 2025 Member, Association of American Physicians
  • 2023 Jeff Toughill Award, The Histiocytosis Association
  • 2022 President, Histiocyte Society
  • 2020  President-elect, Histiocyte Society
  • 2014 Alex’s Lemonade Stand Foundation Infrastructure Award, Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia
  • 2013 William B Lawrence & Blanche Hughes Award
  • 2013 Nezelof Prize for Basic Research, The Histiocyte Society
  • 2013 Alex’s Lemonade Stand Foundation Innovation Award, Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia
  • 2012 Alex’s Lemonade Stand Foundation Innovation Award, Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia
  • 2011 Member, Society for Pediatric Research
  • 2011 Center for Integration of Genetic Healthcare Technologies Award, University of Pennsylvania Perelman School of Medicine, Philadelphia
  • 2010 Foerderer Award, The Children’s Hospital of Philadelphia
  • 2008 XLP Research Trust Award, London, England
  • 2002 American Society of Hematology Junior Faculty Scholar Award

Research Interests

  • Identifying novel genetic causes of childhood cancer
  • Optimizing methods of tumor surveillance for children with increased cancer risk
  • Evaluating the factors that influence parent and adolescent decision making and communication around genetic testing for heritable cancer risk
  • Understanding the behavioral and psychological impacts of cancer genetic testing on children and their families
  • Increasing understanding and developing new therapies for malignant and non-malignant hematologic disorders, including B-cell leukemias and lymphomas, hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated lymphoproliferations

Clinical Trials

Recruiting
Published results
G4K: Genomes for Kids

Study goal:

The main goal of this study is to learn more about the reasons childhood tumors form and how to treat them better.

Recruiting
SJFAMILY: Study of Cancer in Families

Study goal:

The main purpose of this trial is to learn about the genetic causes of cancer. 

Age:

Younger than 50 years old

HLHRUXO: Ruxolitinib Therapy for HLH

Study goal:

This main goal of this study is to find out if ruxolitinib will improve the survival rate for children with HLH.

Age:

6 weeks to 22 years old

Dr. Nichols in Progress

Dr. Nichols in St. Jude News